profit from every CHF 100 of sales.
CHF 0CHF 100
PolyPeptide Group
CHF 40.35-0.12% today
+59.5% in 1 year
1-year low CHF 23.751-year high CHF 49.40
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What PolyPeptide Group sold, what it kept, and what it did with the cash.
Sales went from €283 million in 2022 to €392 million in 2025, with -€21.2 million of profit last year.
SalesProfit
PolyPeptide Group vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| PolyPeptide Group | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads PolyPeptide Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 283 | 325 | 339 | 392 | |
| 54 | 9 | 39 | 67 | |
| 13 | -34 | -6 | 9 | |
| 36 | -22 | 24 | 28 | |
| 8 | -51 | -20 | -21 | |
| 0.24 | -1.56 | -0.59 | -0.64 | |
| 19.2% | 2.8% | 11.6% | 17.0% | |
| 4.5% | -10.4% | -1.8% | 2.2% | |
| 2.7% | -15.8% | -5.8% | -5.4% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 576 | 689 | 757 | 826 |
| Cash | 38 | 96 | 68 | 75 |
| Total debt | 21 | 114 | 94 | 131 |
| Total liabilities | 154 | 308 | 399 | 485 |
| 422 | 381 | 357 | 341 | |
| 33 | 33 | 33 | 33 | |
| 1.9% | -9.0% | -1.7% | -1.8% | |
| 1.8% | -13.5% | -5.5% | -6.2% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 5 | 36 | 89 | 78 | |
| 79 | 57 | 87 | 109 | |
| -73 | -20 | 2 | -31 | |
| Dividends paid | 10 | – | – | – |
| 14 | 0 | 0 | 0 | |
| 1 | 1 | 1 | 2 |
Valuation
- –
- –
- –
- 3.3×
- 3.7×
- –
- 52.8×
- -2.2%
- -1.5%
- –
Profitability
- 17.0%
- 2.2%
- -5.4%
- –
- -1.8%
- -2.7%
- –
- –
- –
- –
Growth
- +11.4%
- –
- –
- –
- +0.0%
Financial health
- 2.0×
- 0.38
- –
- -0.9×
- 1.74
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 31%of 952
Bottom 30%of 884
Top 47%of 886
Bottom 28%of 987
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
27No pass
Philip Fisher
34No pass
Peter Lynch
45No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
35No pass
Questions about PolyPeptide Group
Is PolyPeptide Group a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the PolyPeptide Group AI analysis
What does PolyPeptide Group do?
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. It is in Drug Manufacturers - Specialty & Generic, based in Baar, Switzerland, with 1,440 employees.
Is PolyPeptide Group stock halal?
Yes. PolyPeptide Group passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
How has PolyPeptide Group stock done over the past year?
Up 59.5% over the past twelve months, to CHF 40.35. It traded between CHF 23.75 and CHF 49.40 and is 18.3% below its high.
Who are PolyPeptide Group's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with PolyPeptide Group's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.